AstraZeneca’s COVID-19 vaccine has been found to be highly effective in stopping the development of Covid-19 symptoms. As per the trial results, the vaccine has been found to offer 70% to 90% protection against the virus based on the dosage. We have provided below a detailed overview of the expected timelines when the given countries are likely to receive doses of AstraZeneca’s COVID-19 vaccine.
Also, check out our research on;
- COVID-19 Vaccine – Moderna; Timeline in U.S., U.K., E.U., China, Japan & Canada
- COVID-19 Vaccine – Pfizer; Timeline in U.S., U.K., E.U., China, Japan & Canada
- COVID-19 Vaccine – Novavax; Timeline in U.S., U.K., E.U., China, Japan & Canada
- COVID-19 Vaccine – Janssen; Timeline in U.S., U.K., E.U., China, Japan & Canada
- COVID-19 Vaccination Plans: Nebraska, Nevada, New Hampshire
- COVID-19 Vaccination Plans: New Jersey, New Mexico, New York
- COVID-19 Vaccination Plans: North Carolina, North Dakota, Ohio
- COVID-19 Vaccination Plans: Oklahoma, Oregon, Rhode Island
- COVID-19 Vaccination Plans: South Carolina, South Dakota, Tennessee
- COVID-19 Vaccination Plans: Texas, Utah, Vermont
- COVID-19 Vaccination Plans: Virginia, Washington, West Virginia
- COVID-19 Vaccination Plans: Wisconsin, Wyoming
- COVID-19 Vaccination Plans: Alabama, Alaska, Arizona
- COVID-19 Vaccination Plans: Arkansas, California, Colorado
- COVID-19 Vaccination Plans: Connecticut, Delaware, Florida
- COVID-19 Vaccination Plans: Georgia, Idaho, Illinois
- COVID-19 Vaccination Plans: Indiana, Iowa, Kansas
- COVID-19 Vaccination Plans: Kentucky, Louisiana, Maine
- COVID-19 Vaccination Plans: Maryland, Massachusetts, Michigan
- COVID-19 Vaccination Plans: Mississippi, Missouri, Montana
- COVID-19 Vaccine for African Americans
- U.S Vaccine Roll-Out Information
- How U.S. Federal and State Governments are Supporting Employees During the Coronavirus Pandemic
- The Use of Contact Tracing to Fight COVID-19
- Flu/Covid Testing Products
- As per an article by Bloomberg, the UK government has purchased 100 million doses of Oxford-Astrazeneca’s COVID-19 vaccine in advance, and according to Prime Minister Boris Johnson, “the majority of people, most in need of vaccination in the UK might be able to get one by Easter (April 2021).” Nearly 4 million additional doses of the vaccine are expected to be available in the UK by year-end, and another 40 million by the end of March 2021.
- Also, as per the above-mentioned Bloomberg article from November, the UK hopes to be able to begin its mass vaccination program next month (December) by speeding up the regulatory approval process.
- The vaccine is currently waiting for approval by regulators who will assess the vaccine’s safety, effectiveness, and that it is manufactured to high standards for a temporary supply. The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for assessing the vaccine for authorization under Regulation 174 of the Human Medicines Regulations. According to the latest statement by the Chairman of the UK’s National Health Service on December 12, the vaccine will hopefully be approved by the regulators within a matter of days.
- AstraZeneca has entered into an agreement with the European Commission (EC) to supply up to 400 million doses of its AZD1222 COVID-19 vaccine. The first doses are expected to be delivered by the end of 2020.
- Italy is likely to receive 4 million shots of AstraZeneca’s COVID-19 vaccine as early as January 2021, and it will receive a further 12 million vaccine doses within the following three months by April 2021. A total of 70 million doses will be received by June 2021.
- According to Spain’s Health Minister Salvador Illa, the country is likely to receive 31.6 million doses of AstraZeneca’s COVID-19 vaccine between December 2020 and June 2021.
- Germany expects the coronavirus vaccine to be available in the first quarter of 2021 at the earliest. The country has not specified any specific timeline for AstraZeneca’s COVID-19 vaccine and is currently studying all seven potential vaccines, which are expected to complete testing this year or next.
- As per an article by Reuters, AstraZeneca’s vaccine is likely to be approved in China by mid-2021, and the company has partnered with the Chinese private vaccine manufacturer Shenzhen Kangtai Biological Products Co Ltd to produce the vaccine.
- The company is expected to deliver 100 million doses of the COVID-19 vaccine candidate AZD1222 by the end of 2020. Additionally, 200 million doses are expected to be delivered by the end of 2021 in China.
- As per an article by Reuters, the Japanese government has entered into an agreement with AstraZeneca to receive 120 million doses of the vaccine in 2021, with 30 million doses to be received by March 2021.
- AstraZeneca has partnered with JCR Pharma, a Japanese pharmaceutical company, to help make a portion of the potential COVID-19 vaccine. The company will also import vaccine shots as part of its deal to supply Japan.
- As per an article by iPolitics, the Canadian government can pre-order doses of AstraZeneca’s COVID-19 vaccine before the end of 2020 if the vaccine continues to show promising results in its clinical trials.
- The Canadian government has agreed to buy 20 million doses of AstraZeneca’s COVID-19 vaccine once it is tested safe. However, Canadian officials have not yet disclosed any precise timelines for the delivery of the vaccine.
- The US government has signed a deal with AstraZeneca for 300 million doses of the COVID-19 vaccine to be made available by early next year. It was initially scheduled to be received in Fall 2020.
- As per the chief scientific officer of Operation Warp Speed, AstraZeneca Plc, along with J&J, is likely to provide 150 million to 200 million vaccine shots in the first quarter of 2021 in the US.
To compile the required information, we scoured through the various media articles from Forbes, WSJ, Bloomberg, Reuters, BBC News, CNBC, The Global Mail, Business Standard, and The Guardian, among others. We also looked through the government and health ministry websites of the respective countries, along with research publications from Goldman, McKinsey, Deloitte, Forrester, etc. Lastly, we also searched through various pharma blogs like Pharma Press, Pharma Times, European Pharmaceutical Review, and Pharmaceutical Journal, among others. After an exhaustive search through the above-mentioned sources, we were unable to find relevant information for Canada. The only available data for Canada was about its agreement with AstraZeneca to buy 20 million doses of the vaccine. No specific timeline for the delivery of the vaccine has yet been disclosed by the officials.